Breaking News Instant updates and real-time market news.

GEMP

Gemphire Therapeutics

$7.32

-0.21 (-2.79%)

, PFE

Pfizer

$41.05

0.52 (1.28%)

16:04
08/06/18
08/06
16:04
08/06/18
16:04

Gemphire in amended license pact with Pfizer

Gemphire Therapeutics (GEMP) announced that it has amended and restated the license agreement with Pfizer (PFE) covering gemcabene. Gemphire licensed exclusive worldwide commercial rights to gemcabene from Pfizer in an agreement signed in April 2011. Under the original agreement, Pfizer had the right to terminate the license if the drug was not adequately commercialized by April 2021. The amended and restated agreement contains a number of changes to the license, including extending the date of the agreed deadline for the first commercial sale. As amended, Pfizer has the right to terminate the license if the first commercial sale has not occurred by April 2024. The royalty period in countries in which gemcabene becomes approved for commercial sale, if any, has been extended, and the royalty rates that are payable upon achieving certain aggregate sales levels of gemcabene have increased slightly, ranging from the high single digits to the mid-teens depending on the level of net sales, in consideration for such extension."We are pleased to enter into this amended and restated agreement with Pfizer that includes provisions that we believe benefit both parties," said Dr. Steven Gullans, CEO of Gemphire. "The extension to the agreed date by which we need to commercialize gemcabene provides us with additional flexibility to focus on the optimal development path and timeline for gemcabene. Additionally, we believe the extension will remove any near-term considerations by investors and potential strategic partners about our ability to achieve commercialization under the license agreement. Based on our current projections, however, we believe we will be successful in bringing gemcabene to market in at least one of our chosen disease indications well before this date."

GEMP

Gemphire Therapeutics

$7.32

-0.21 (-2.79%)

PFE

Pfizer

$41.05

0.52 (1.28%)

  • 22

    Aug

  • 10

    Sep

GEMP Gemphire Therapeutics
$7.32

-0.21 (-2.79%)

07/27/18
ROTH
07/27/18
NO CHANGE
Target $40
ROTH
Buy
Gemphire Therapeutics price target raised to $40 from $30 at Roth Capital
Roth Capital analyst Yasmeen Rahimi raised her price target for Gemphire Therapeutics to $40 from $30 based on a positive forecast for the company's lead molecule in the pediatric NASH trial. In a research note to investors, Rahimi projects $415M peak sales for gemcabene for pediatric NASH in the U.S. in 2028 based on assumptions that include ~7.5M children with NAFLD among which 25% progress to NASH of which 12% have advanced NASH, as well as a U.S. launch in 2022 in 4% with peak market penetration of 55%. Rahimi, who has a Buy rating on Gemphire, sees top-line six-month histology results for the 24-week Phase 2a study in eight NASH patients with familial partial lipodystrophy in the fall, which will give clearer and early indications of gemcabene's effects on biopsy.
05/16/18
RAJA
05/16/18
INITIATION
Target $22
RAJA
Outperform
Gemphire Therapeutics initiated with an Outperform at Raymond James
Raymond James analyst Laura Chico initiated Gemphire Therapeutics with an Outperform and $22 price target saying its gemcabene offs a potentially differentiated profile in the dyslipidemia space, which should narrow the gap versus peers with successful data.
01/26/18
HCWC
01/26/18
NO CHANGE
Target $28
HCWC
Buy
Gemphire Therapeutics price target raised to $28 from $22 at H.C. Wainwright
H.C. Wainwright analyst Ed Arce raised his price target for Gemphire Therapeutics to $28 saying he sees a "catalyst-rich" 2018 for the company. The analyst says his confidence grows in the emerging multiple mechanisms of the compound as the gemcabene pipeline expands. He keeps a Buy rating on Gemphire Therapeutics.
12/22/17
ROTH
12/22/17
NO CHANGE
Target $30
ROTH
Buy
Gemphire transition to NASH a value creator, says Roth Capital
Roth Capital analyst Yasmeen Rahimi views Gemphire Therapeutics' transition into non-alcoholic steatohepatitis as an "important shareholder value creator." After the company announced the launch of proof-of-concept Phase 2a trial of gemacabene in eight patients with familial partial lipodystrophy, a rare genetic metabolic condition characterized by abnormal distribution of subcutaneous fat which then leads to NASH, the analyst keeps a Buy rating on Gemphire with a $30 price target.
PFE Pfizer
$41.05

0.52 (1.28%)

07/18/18
WELS
07/18/18
NO CHANGE
WELS
Novartis report has negative read through for Teva, Mylan, says Wells Fargo
Wells Fargo analyst David Maris noted that Novartis (NVS) lowered its 2018 guidance for Sandoz along with its Q2 report and reportedly told Bloomberg that it would consider selling the generic drug unit. He sees a negative read through for companies with large U.S. commodity generic exposure, such as Teva (TEVA) and Mylan (MYL), from Novartis' report, Maris tells investors. He also noted that Novartis said it will not increase prices on its drugs in the U.S. for the rest of 2018, as Pfizer (PFE) recently has also said, calling this "a wise approach and correct read of the increasing intensity of the scrutiny around rising healthcare costs." Maris continues to expect the " chilling effect" on price increases to spread through the industry. Lastly, the analyst pointed out that the Amgen-partnered (AMGN) launch of Aimovig is off to a strong start, which he believes bodes well for Teva's fremanezumab and Eli Lilly's (LLY) galcanezumab.
07/18/18
PIPR
07/18/18
NO CHANGE
Target $450
PIPR
Overweight
Piper maintains Overweight on Regeneron on tanezumab news
Piper Jaffray analyst Christopher Raymond keeps an Overweight rating on Regeneron Pharmaceuticals (REGN) on news that tanezumab, Pfizer (PFE) and Eli Lilly's (LLY) anti-NGF antibody that is a competitor to Regeneron's fasinumab, successfully completed the first of several Phase 3 trials. Fasinumab remains an unmodeled opportunity, but the read-through from tanezumab is positive and the market for an effective, non-opioid chronic pain treatment is "massive," Raymond tells investors in a research note. The analyst points out that Regeneron and Teva (TEVA) still expect to report Phase 3 data starting later this year. Raymond keeps an Overweight rating on Regeneron with a $450 price target.
07/17/18
CANT
07/17/18
NO CHANGE
CANT
Overweight
Aclaris offers best risk/reward of hair loss players, says Cantor Fitzgerald
The potential for JAK inhibitors to treat alopecia areata may be underappreciated by investors because the Street does not appear to be ascribing enough value to the opportunity, Cantor Fitzgerald analyst Louise Chen tells investors in a research note. Of the three companies she covers developing JAKs for hair loss, Aclaris Therapeutics (ACRS), Eli Lilly (LLY) and Pfizer (PFE), the analyst believes Aclaris offers the best risk/reward and greatest upside potential. The company has a market cap below $700M and two potential "shots on goal" for alopecia areata, Chen writes. She estimates combined peak sales of $1B-plus for both opportunities and keeps an Overweight rating on Aclaris. The physicians the analyst spoke to believe the company's JAKs for hair loss will work.
07/17/18
HCWC
07/17/18
NO CHANGE
Target $42
HCWC
Buy
uniQure pullback on Pfizer study unwarranted, says H.C. Wainwright
H.C. Wainwright analyst Debjit Chattopadhyay notes that shares of uniQure (QURE) dropped 11% yesterday after Pfizer (PFE) initiated an "open-label, non-investigational product, multi-center, lead-in study to evaluate at least 6 months of prospective efficacy and selected safety data of factor IX prophylaxis replacement therapy in moderate to severe adult Hemophilia B subjects who are negative for neutralizing antibodies to adeno-associated virus vector-spark100". This has been potentially misconstrued as the initiation of the Phase 3 study, suggesting competitive threats for uniQure earlier than anticipated, Chattopadhyay tells investors in a research note. However, this is not to be mistaken as a gene therapy Phase 3 program, as there is no gene therapy treatment cohort, the analyst adds. Further, Chattopadhyay points out that Pfizer's observation study is expected to be completed during November of 2020, which he believes puts uniQure at least a year, if not more, ahead. In addition, the analyst continues to believe that Pfizer is likely to encounter intellectual property headwinds given uniQure's patent asset protecting both the mPadua gene cassette and its method of use to treat hemoglobinopathies. He views the selloff yesterday in shares of uniQure as unwarranted and keeps a Buy rating on the name with a $42 price target.

TODAY'S FREE FLY STORIES

21:25
03/25/19
03/25
21:25
03/25/19
21:25
General news
Fed's Rosengren warned that U.S. Q1 growth is likely to be weak »

Fed's Rosengren…

BBBY

Bed Bath & Beyond

$13.87

0.17 (1.24%)

20:44
03/25/19
03/25
20:44
03/25/19
20:44
Periodicals
Activist firms seek to replace Bed Bath & Beyond board, CEO, WSJ says »

Activist funds -Legion…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Apr

RTN

Raytheon

$180.58

-0.82 (-0.45%)

, BA

Boeing

$370.52

8.37 (2.31%)

20:36
03/25/19
03/25
20:36
03/25/19
20:36
Hot Stocks
Raytheon kill vehicle hits ICBM target in first dual-salvo test »

For the first time, the…

RTN

Raytheon

$180.58

-0.82 (-0.45%)

BA

Boeing

$370.52

8.37 (2.31%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    May

20:35
03/25/19
03/25
20:35
03/25/19
20:35
General news
The "Summary of Opinions" from the BoJ's March meeting »

The "Summary of…

WHD

Cactus

$36.03

1.225 (3.52%)

20:27
03/25/19
03/25
20:27
03/25/19
20:27
Hot Stocks
Cactus VP of Operations sells 229K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CCL

Carnival

$56.67

-0.065 (-0.11%)

, MKC

McCormick

$143.88

1.58 (1.11%)

20:25
03/25/19
03/25
20:25
03/25/19
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

CCL

Carnival

$56.67

-0.065 (-0.11%)

MKC

McCormick

$143.88

1.58 (1.11%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Mar

  • 26

    Mar

  • 27

    Mar

CRTO

Criteo

$21.99

-3.4 (-13.39%)

20:19
03/25/19
03/25
20:19
03/25/19
20:19
Downgrade
Criteo rating change at KeyBanc »

Criteo downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SSNLF

Samsung

$0.00

(0.00%)

20:02
03/25/19
03/25
20:02
03/25/19
20:02
Periodicals
Samsung sees weaker environment for display, memory in Q1, Bloomberg says »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BA

Boeing

$370.52

8.37 (2.31%)

19:51
03/25/19
03/25
19:51
03/25/19
19:51
Hot Stocks
U.S. MDA and Boeing Complete Historic Missile Defense Test »

The U.S. Missile Defense…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    May

MCD

McDonald's

$185.66

-1.11 (-0.59%)

19:49
03/25/19
03/25
19:49
03/25/19
19:49
Periodicals
McDonald's purchase price of Dynamic Yield above $300M, Bloomberg says »

The purchase of Dynamic…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Apr

  • 28

    May

SSNLF

Samsung

$0.00

(0.00%)

19:32
03/25/19
03/25
19:32
03/25/19
19:32
Periodicals
Breaking Periodicals news story on Samsung »

Samsung sees Q1 below…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AWR

American States Water

$71.51

0.505 (0.71%)

19:22
03/25/19
03/25
19:22
03/25/19
19:22
Hot Stocks
American States Water CEO sells 12.4K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MEOH

Methanex

$56.35

-1.38 (-2.39%)

19:10
03/25/19
03/25
19:10
03/25/19
19:10
Hot Stocks
Methanex confirms receipt of director nominees notice from M&G »

Methanex Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BECN

Beacon Roofing

$34.14

0.81 (2.43%)

, SAEX

SAExploration

$4.03

0.13 (3.33%)

18:55
03/25/19
03/25
18:55
03/25/19
18:55
Hot Stocks
Fly Intel: After Hours Movers »

DOWN AFTER EARNINGS:…

BECN

Beacon Roofing

$34.14

0.81 (2.43%)

SAEX

SAExploration

$4.03

0.13 (3.33%)

IQ

iQIYI

$24.01

-0.86 (-3.46%)

MYOK

MyoKardia

$51.87

-2.44 (-4.49%)

CTMX

CytomX Therapeutics

$10.76

0.33 (3.16%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Mar

  • 26

    Mar

  • 21

    May

  • 27

    Mar

HPQ

HP Inc.

$18.97

-0.4 (-2.07%)

18:48
03/25/19
03/25
18:48
03/25/19
18:48
Periodicals
HP lawyer tells court Autonomy's Lynch inflated sales data, Reuters says »

A lawyer for HP told a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

PEGA

Pegasystems

$63.61

-0.27 (-0.42%)

18:45
03/25/19
03/25
18:45
03/25/19
18:45
Hot Stocks
Pegasystems CEO: We are massively changing our marketing strategy »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

SMTC

Semtech

$52.59

-0.38 (-0.72%)

18:32
03/25/19
03/25
18:32
03/25/19
18:32
Hot Stocks
Semtech CEO sells 25K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

TMO

Thermo Fisher

$268.89

5.015 (1.90%)

18:24
03/25/19
03/25
18:24
03/25/19
18:24
Hot Stocks
Thermo Fisher CEO: We have a very disciplined M&A process »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DJX

Dow Jones Industrial Average

$0.00

(0.00%)

, SPX

S&P 500

$0.00

(0.00%)

18:24
03/25/19
03/25
18:24
03/25/19
18:24
Periodicals
Parliament forces votes on Brexit plan options, Bloomberg reports »

Lawmakers of U.K.…

DJX

Dow Jones Industrial Average

$0.00

(0.00%)

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$278.99

-0.56 (-0.20%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MCD

McDonald's

$185.66

-1.11 (-0.59%)

18:23
03/25/19
03/25
18:23
03/25/19
18:23
Hot Stocks
McDonald's to acquire Dynamic Yield, terms not stated »

McDonald's announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Apr

  • 28

    May

BA

Boeing

$370.52

8.37 (2.31%)

18:22
03/25/19
03/25
18:22
03/25/19
18:22
Periodicals
Boeing software fix to prevent repeated activiation of MCAS, Reuters says »

A Boeing software repair…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    May

ACHC

Acadia

$29.47

-0.59 (-1.96%)

17:58
03/25/19
03/25
17:58
03/25/19
17:58
Hot Stocks
Acadia says President Brett Turner leaving by mutual agreement »

Brent Turner, President…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$188.78

-2.33 (-1.22%)

17:41
03/25/19
03/25
17:41
03/25/19
17:41
Recommendations
Apple analyst commentary at Piper Jaffray »

Apple price target raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

  • 03

    Jun

ZFGN

Zafgen

$2.70

-0.15 (-5.26%)

17:38
03/25/19
03/25
17:38
03/25/19
17:38
Hot Stocks
Armistice Capital reports 5.6% passive stake in Zafgen »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NOC

Northrop Grumman

$268.56

0.27 (0.10%)

17:36
03/25/19
03/25
17:36
03/25/19
17:36
Hot Stocks
Northrop Grumman awarded $245.05M Navy contract modification »

Northrop Grumman has been…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.